-
The benefit of the ch14.18 antibody is that it has been shown in laboratory studies to be just as effective at targeting neuroblastoma cells as its murine counter parts. Ch14.18 has even been shown to induce lysis of neuroblastoma cells through the process of ADCC and CDC better than its murine counterpart...
-
The ch14.18 antibody has been used in clinical trials both as a single agent and in combination with augmenting agents (cytokines) GM-CSF and IL-2. The chimeric antibody has also been tested as a single-agent therapy in two separate trials involving patients with stage 4 neuroblastoma. In a Phase I trial...
-
Although the ch14.18 and 3F8 antibodies both share the same target on neuroblastoma cells, the GD2 antigen, there are significant differences between them. The two antibodies differ in structure, in protocol design and availability, in comparisons of study results, and in method of administration. For...
-
Chimeric Monoclonal Antibody 14.18 (ch14.18) is an antibody that is part human and part mouse. It is a chimeric composed of the murine (mouse) monoclonal antibody 14.G2a and human constant region genes. The 14G2a antibody is a variant of the murine 14.18 IgG3 antibody targeted to the GD2 antigen. 14GD2a...
-
Antibody therapy is believed to rely on three different methods to kill neuroblastoma cells. These are called antibody dependent cell-mediated cytotoxicity (ADCC), complement mediated cytotoxicity (CMC), and passive immunotherapy using the anti-idiotypic network. The names sound much scarier that it...
-
One of the great things about being a mouse is the fact that mice do not naturally get neuroblastoma. Mice develop antibodies that attach to neuroblastoma cells thus alerting the immune system to come and kill the tumor cell. Neuroblastoma cells get killed before they even get a chance to turn into tumors...